ERBB2 and breast carcinoma: Initially, in 2011–2013, the oncologist proposed the molecular basis for the treatment of early breast cancer, which defined luminal A breast cancer patients as having a estrogen receptor (ER) positive, progesterone receptor (PR) positive (20%), HER2 negative, and Ki67 positivity of <14% [9,10].